Related Experiment Video
Updated: Aug 11, 2026
10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 19, 2013
STI571: a gene product-targeted therapy for leukemia
1Leukemia Program, Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health Sciences University, OP28, 3181 SW Sam Jackson Park Road, Portland, OR 97201, USA. maurom@ohsu.edu
Current Oncology Reports
|April 11, 2001
Summary
Chronic myelogenous leukemia (CML) is a blood stem cell disorder. A new drug, STI571, targets the bcr-abl tyrosine kinase, offering hope for CML patients.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Chronic myelogenous leukemia (CML) is a clonal hematopoietic stem-cell disorder.
- It is characterized by the (9:22) translocation, leading to the production of the bcr-abl tyrosine kinase.
- CML typically presents with myeloid proliferation and can progress to acute leukemia.
Purpose of the Study:
- To introduce STI571, a novel bcr-abl tyrosine kinase inhibitor.
- To highlight STI571 as a paradigm for targeted cancer therapy.
- To discuss the potential of STI571 in expanding treatment options for CML patients.
Main Methods:
- Rational drug development approach.
- Development of a specific inhibitor targeting the bcr-abl tyrosine kinase.
Main Results:
- STI571 has emerged as a promising therapeutic agent.
- The drug represents a new hope for patients with CML.
Conclusions:
- STI571 offers a targeted therapy approach for CML.
- This development expands treatment possibilities for CML patients.
- Gene product-targeted therapy shows significant promise in oncology.
Related Concept Videos
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...